FDA Approval for CKD
Farxiga (dapagliflozin), an SGLT2 inhibitor, is FDA-approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease (CKD) at risk of progression, regardless of diabetes status. This approval came in 2023 based on the DAPA-CKD trial, which showed a 39% relative risk reduction in the primary composite endpoint (sustained eGFR decline ≥50%, end-stage kidney disease, or kidney/cardiovascular death) versus placebo.[1][2]
Key Evidence from DAPA-CKD Trial
In the phase 3 DAPA-CKD study (n=4,304 patients with CKD stages 2-4, eGFR 25-75 mL/min/1.73m²), Farxiga reduced major kidney and cardiovascular events by 39% (HR 0.61, 95% CI 0.51-0.72). Benefits held across eGFR levels down to 25 mL/min/1.73m² and with or without type 2 diabetes. Trial duration averaged 2.4 years; common risks included acute kidney injury (4.7% vs 3.7% placebo) but no increase in kidney failure overall.[1][3]
Common Risks and Safety Profile in CKD
Farxiga carries risks relevant to CKD patients:
- Volume depletion (worsened by diuretics or low blood pressure).
- Acute kidney injury, especially if dehydrated.
- Ketoacidosis (rare, even with normal blood sugar).
- Lower urinary tract infections and genital mycotic infections.
- Amputations (black box warning from diabetes trials, though not elevated in DAPA-CKD).
Contraindicated in severe renal impairment (eGFR <25 mL/min/1.73m²) or on dialysis. Monitor eGFR, volume status, and electrolytes; start at 10 mg daily.[2][4]
How Does Farxiga Compare to Other CKD Treatments?
| Treatment | Mechanism | CKD Benefit Evidence | Key Risks in CKD |
|-----------|-----------|----------------------|------------------|
| Farxiga (dapagliflozin) | SGLT2 inhibitor | DAPA-CKD: 39% risk reduction | AKI, volume depletion |
| Jardiance (empagliflozin) | SGLT2 inhibitor | EMPA-KIDNEY: 28% risk reduction | Similar to Farxiga |
| Finerenone (Kerendia) | Non-steroidal MRA | FIDELIO/FIGARO: 18% kidney risk reduction | Hyperkalemia |
| Verquvo (vericiguat) | sGC stimulator | VICTORIA: Heart failure focus, modest CKD benefit | Hypotension |
SGLT2 inhibitors like Farxiga outperform placebo in head-to-head CKD data; guidelines (KDIGO 2024) recommend them as first-line for CKD with proteinuria.[3][5]
When to Avoid or Monitor Closely
Avoid in polycystic kidney disease, solitary kidney, or prior laser foot amputation. Use caution with eGFR 25-45 mL/min/1.73m² due to reduced efficacy on glycemic control but preserved kidney/cardiac benefits. KDIGO suggests discontinuing if eGFR falls below 20-25 mL/min/1.73m².[5] Real-world data show 10-15% discontinuation rate in CKD due to side effects.[6]
What Patients Report About Side Effects
Patient forums and registries note dehydration (thirst, dizziness) as the top issue, resolving with fluids. Fewer infections than feared; some report sustained eGFR stabilization after 6-12 months. Long-term data beyond 4 years limited.[6]
[1]: NEJM - DAPA-CKD Trial
[2]: FDA Label - Farxiga
[3]: KDIGO 2024 CKD Guideline
[4]: AstraZeneca Prescribing Info
[5]: NEJM - EMPA-KIDNEY
[6]: JAMA Network Open - Real-World SGLT2i in CKD